Results 141 to 150 of about 450,538 (349)
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
Arthritis &Rheumatology, EarlyView.Objective
To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods
In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...Carol A. Langford, Nader Khalidi, Jason Springer, Marcia Friedman, Bernhard Hellmich, Christian Pagnoux, Natasha Dehghan, Ora Gewurz‐Singer, Curry L. Koening, Yih Chang Lin, Paul A. Monach, Larry W. Moreland, Aurore Fifi‐Mah, Oliver Flossmann, Lindsy J. Forbess, Peter Lanyon, Eamonn Molloy, Ulrich Specks, Robert Spiera, Elaine Yacyshyn, Carol A. McAlear, Cristina Burroughs, Rachel B. Jones, Rennie L. Rhee, Rula Hajj‐Ali, Kenneth J. Warrington, David Cuthbertson, Jeffrey P. Krischer, David Jayne, Peter A. Merkel, for the Vasculitis Clinical Research Consortium and the European Vasculitis Society, Eric Stratton, Marcin Trojanowski, Chris Zammitti, Jessica Ziemek, Javier Ache, Marianne Bernardo, Bryan Gonzalez, Mariko Ishimori, Bonnie Paul, Mahbuba Tusty, Swamy Venuturupalli, Daniel Wallace, Michael Weisman, Debora Bork, Tiffany Clark, Sonya Crook, Kathleen Gartner, Lori Strozniak, Elizabeth Kisela, Marcia Leon, Loretta Williams, Jeff Negrey, Hannah Thome, Andrew Wiecek, Beemnet Amdemicael, Emily Bakaj, Aliza Bloostein, Annel Fernandez, Chris Hatzis, Lindsay Lally, Misbah Baqir, Cynthia Beinhorn, Shannon Daley, Sue Donlinger, Samantha Fatis, Yeoniee Kim, Matthew Koslow, Matthew J. Koster, Kathleen Mieras, Tobias Peikert, Michael Stachowitz, Gwen E. Thompson, Medius Klinik Kirchheim, Nicole Hollinger, Nina Kempiners, Hartmut Mahrhofer, Anke Reichelt de Tenorio, Bastian Walz, Banita Aggarwal, Simon Carette, Nazrana Haq, Samyukta Jagadeesh, Suneet Khurana, Judy Vendramini, Amanda Butler, Mithun Chakravorty, Paige Draper, Cattleya Godsave, Marie‐Josèphe Pradère, Megan Rutter, Alan Thomas, Rebekah Alexander, Cong‐Qiu Chu, Daniela Ghetie, Amy Jeon, Michelle Jin, Kim Phung Nguyen, Brenda Olmos, Kelly Peel, Rosy Quinn, Cailin Sibley, Mayamol Joseph, Deepa Thapa, Sandra Messier, Diane Robins, Jayamarx Jayaraman, Kam Shojania, Richard Conway, Kathy Brickell, Phil Gallagher, Alison Clifford, Sylvia Gaucher, Ainslie Hildebrand, Karen Martins, Breanne Stewart, Stephen Chaudary, Namneet Sandhu, Stephen Williams, Karen Dahlsveen, Seerapani Gopaluni, Cecilia Matara, Mark McClure, Rona Smith, Amrita Bath, Leslie Glasco, Theresa Howard, Caitlin McMillian, Na Yu, Mingcai Zhang, Ruba Kado, Emily Lewis, W. Joseph McCune, Emily Siegwald, Jennifer Sylvester, Naomi Amudala, Kathryn Doyle, Matthew MacDonald, Leah Madden, Brian Rice, Antoine Sreih, Sally Thompson, Laurie Hope, Kimberly Liang, Douglas Lienesch, Niveditha Mohan, Kelly Reckley, John Carter, Gail Lewis, Michelle Orzechowski, Martha Finco, Jennifer Godina, Jessica Gonzalez, Julieanne Hall, Nereida Ortez, Gopi Penmetsa +155 morewiley +1 more sourceUrinary alkalisation for uncomplicated urinary tract infection (Protocol) [PDF]
, 2013 Bleidorn, Brumfitt, Burian, Carlsson, Foxman, Foxman, Franz, Gupta, Higgins, Mazzulli, Munday, Richards, Spooner, Zhanel +13 morecore +1 more sourceB cells and systemic sclerosis interstitial lung disease
Arthritis &Rheumatology, Accepted Article.Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...Nina Goldman, Voon Ong, Christopher Denton +2 morewiley +1 more sourceA phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Arthritis &Rheumatology, Accepted Article.Background
Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers +33 morewiley +1 more sourceComparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study
Arthritis &Rheumatology, Accepted Article.Objectives
The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods
This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian +35 morewiley +1 more source
